The United States of America, As Represented by the Secretary, Department of Health and Human Services

Louisiana State University and Agricultural & Mechanical College

The UAB Research Foundation (The University of Alabama at Birmingham)

Wake Forest University

Loma Linda University

The University of Alabama

Rakesh P Patel

David J Lefer

Mark Thomas Gladwin

Daniel B Kim-Shapiro

Edward H Oldfield

Alan N Schechter

Richard O Cannon, Iii

Christian J Hunter

Gordon G Power

Ryszard Marek Pluta

Christopher Kevil

Jeffrey Kerby

Richard O Cannon

Ryszard Pluta

Methods of treating a subject who has chronic tissue ischemia are disclosed. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to result in blood vessel growth in the ischemic tissue. The subject can be diagnosed as having a medical condition that results in persistent or recurring restriction of blood supply to a tissue, for example, peripheral artery disease, diabetes, atherosclerotic cardiovascular disease or defective wound healing. The methods can include the step of identifying a suitable subject.

Use of nitrite salts in chronic ischemia

It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.

Use of nitrite salts for the treatment of cardiovascular conditions

This disclosure relates to methods of using nitrite to detoxify stroma-free hemoglobin based blood substitutes. In particular, methods are described for using a blood substitute comprised of about equimolar amounts of nitrite and hemoglobin (e.g., nitrite-metHb) to treat, prevent, or ameliorate diseases of the blood in a subject, or as a blood replacement in a subject.

Nitrite and nitrite-metheme therapy to detoxify stroma-free hemoglobin based blood substitutes

Growing community of inventors

Birmingham, AL, United States of America

Rakesh P Patel